206 related articles for article (PubMed ID: 10980120)
1. Highly invasive transitional cell carcinoma of the bladder in a simian virus 40 T-antigen transgenic mouse model.
Grippo PJ; Sandgren EP
Am J Pathol; 2000 Sep; 157(3):805-13. PubMed ID: 10980120
[TBL] [Abstract][Full Text] [Related]
2. Urothelium-specific expression of an oncogene in transgenic mice induced the formation of carcinoma in situ and invasive transitional cell carcinoma.
Zhang ZT; Pak J; Shapiro E; Sun TT; Wu XR
Cancer Res; 1999 Jul; 59(14):3512-7. PubMed ID: 10416618
[TBL] [Abstract][Full Text] [Related]
3. p53-stabilizing agent CP-31398 prevents growth and invasion of urothelial cancer of the bladder in transgenic UPII-SV40T mice.
Madka V; Zhang Y; Li Q; Mohammed A; Sindhwani P; Lightfoot S; Wu XR; Kopelovich L; Rao CV
Neoplasia; 2013 Aug; 15(8):966-74. PubMed ID: 23908596
[TBL] [Abstract][Full Text] [Related]
4. Different combinations of genetic/epigenetic alterations inactivate the p53 and pRb pathways in invasive human bladder cancers.
Sarkar S; Jülicher KP; Burger MS; Della Valle V; Larsen CJ; Yeager TR; Grossman TB; Nickells RW; Protzel C; Jarrard DF; Reznikoff CA
Cancer Res; 2000 Jul; 60(14):3862-71. PubMed ID: 10919661
[TBL] [Abstract][Full Text] [Related]
5. Identification of genes correlated with early-stage bladder cancer progression.
Stone R; Sabichi AL; Gill J; Lee IL; Adegboyega P; Dai MS; Loganantharaj R; Trutschl M; Cvek U; Clifford JL
Cancer Prev Res (Phila); 2010 Jun; 3(6):776-86. PubMed ID: 20501863
[TBL] [Abstract][Full Text] [Related]
6. Differential expression of progression-related genes in the evolution of superficial to invasive transitional cell carcinoma of the bladder.
Izawa JI; Slaton JW; Kedar D; Karashima T; Perrotte P; Czerniak B; Grossman HB; Dinney CP
Oncol Rep; 2001; 8(1):9-15. PubMed ID: 11115562
[TBL] [Abstract][Full Text] [Related]
7. E-cadherin expression in urothelial carcinoma in situ, superficial papillary transitional cell carcinoma, and invasive transitional cell carcinoma.
Sun W; Herrera GA
Hum Pathol; 2002 Oct; 33(10):996-1000. PubMed ID: 12395372
[TBL] [Abstract][Full Text] [Related]
8. Altered mRNA expression of the Rb and p16 tumor suppressor genes and of CDK4 in transitional cell carcinomas of the urinary bladder associated with tumor progression.
Quentin T; Henke C; Korabiowska M; Schlott T; Zimmerman B; Kunze E
Anticancer Res; 2004; 24(2B):1011-23. PubMed ID: 15161057
[TBL] [Abstract][Full Text] [Related]
9. Canine invasive transitional cell carcinoma cell lines: in vitro tools to complement a relevant animal model of invasive urinary bladder cancer.
Dhawan D; Ramos-Vara JA; Stewart JC; Zheng R; Knapp DW
Urol Oncol; 2009; 27(3):284-92. PubMed ID: 18562222
[TBL] [Abstract][Full Text] [Related]
10. Loss of p53 and acquisition of angiogenic microRNA profile are insufficient to facilitate progression of bladder urothelial carcinoma in situ to invasive carcinoma.
Ayala de la Peña F; Kanasaki K; Kanasaki M; Tangirala N; Maeda G; Kalluri R
J Biol Chem; 2011 Jun; 286(23):20778-87. PubMed ID: 21388952
[TBL] [Abstract][Full Text] [Related]
11. Chemoprevention of urothelial cell carcinoma growth and invasion by the dual COX-LOX inhibitor licofelone in UPII-SV40T transgenic mice.
Madka V; Mohammed A; Li Q; Zhang Y; Patlolla JM; Biddick L; Lightfoot S; Wu XR; Steele V; Kopelovich L; Rao CV
Cancer Prev Res (Phila); 2014 Jul; 7(7):708-16. PubMed ID: 24795386
[TBL] [Abstract][Full Text] [Related]
12. p53 protein and Ki-67 overexpression in urothelial dysplasia of bladder.
Sun W; Zhang PL; Herrera GA
Appl Immunohistochem Mol Morphol; 2002 Dec; 10(4):327-31. PubMed ID: 12607601
[TBL] [Abstract][Full Text] [Related]
13. Overcoming cellular senescence in human cancer pathogenesis.
Yeager TR; DeVries S; Jarrard DF; Kao C; Nakada SY; Moon TD; Bruskewitz R; Stadler WM; Meisner LF; Gilchrist KW; Newton MA; Waldman FM; Reznikoff CA
Genes Dev; 1998 Jan; 12(2):163-74. PubMed ID: 9436977
[TBL] [Abstract][Full Text] [Related]
14. P53 accumulation in precursor lesions and early stages of bladder cancer.
Schmitz-Dräger BJ; van Roeyen CR; Grimm MO; Gerharz CD; Decken K; Schulz WA; Bültel H; Makri D; Ebert T; Ackermann R
World J Urol; 1994; 12(2):79-83. PubMed ID: 8087143
[TBL] [Abstract][Full Text] [Related]
15. [Proliferative activity and p53 expression in transitional cell carcinoma of the urinary bladder].
Offner FA; Schäfer G; Hittmair A; Ofner D; Grünewald K; Weyrer K; Mattern D; Eberle J; Mikuz G; Feichtinger H
Verh Dtsch Ges Pathol; 1993; 77():241-6. PubMed ID: 7511289
[TBL] [Abstract][Full Text] [Related]
16. P53 overexpression in bladder urothelial neoplasms: new aspect of World Health Organization/International Society of Urological Pathology classification.
Kalantari MR; Ahmadnia H
Urol J; 2007; 4(4):230-3. PubMed ID: 18270948
[TBL] [Abstract][Full Text] [Related]
17. Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma.
Chatterjee SJ; Datar R; Youssefzadeh D; George B; Goebell PJ; Stein JP; Young L; Shi SR; Gee C; Groshen S; Skinner DG; Cote RJ
J Clin Oncol; 2004 Mar; 22(6):1007-13. PubMed ID: 14981105
[TBL] [Abstract][Full Text] [Related]
18. Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma.
Shariat SF; Ashfaq R; Sagalowsky AI; Lotan Y
J Urol; 2007 Feb; 177(2):481-7; discussion 487. PubMed ID: 17222615
[TBL] [Abstract][Full Text] [Related]
19. The differential expression of EphB2 and EphB4 receptor kinases in normal bladder and in transitional cell carcinoma of the bladder.
Li X; Choi WW; Yan R; Yu H; Krasnoperov V; Kumar SR; Schuckman A; Klumpp DJ; Pan CX; Quinn D; Gill IS; Gill PS; Liu R
PLoS One; 2014; 9(8):e105326. PubMed ID: 25148033
[TBL] [Abstract][Full Text] [Related]
20. Molecular and kinetic features of transitional cell carcinomas of the bladder: biological and clinical implications.
Baithun SI; Naase M; Blanes A; Diaz-Cano SJ
Virchows Arch; 2001 Mar; 438(3):289-97. PubMed ID: 11315626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
